ACTION ALERT: Urge Johns Hopkins University to accelerate important TB innovation & keep it accessible for all

Please join the Universities Allied for Essential Medicines (UAEM) and other organizations, including the Access Campaign of Doctors Without Borders\Médecins Sans Frontières (MSF), Treatment Action Group (TAG), The Global TB Community Advisory Board (TB CAB) and Public Citizen, in urging Johns Hopkins University (JHU) to commit to a global public health approach in the licensing of sutezolid, a potentially important drug for the treatment of tuberculosis (TB) that was developed at the University.

JHU is currently in discussions with a private company called Sequella about exclusively licensing patents for this potentially life-saving drug. Petitioners are seeking accountability and transparency throughout the process and ask JHU to make the terms and conditions of the licensing agreement available for review both before and after it is finalized. A licensing agreement that does not include necessary provisions to ensure timely development, affordability and accessibility of this medicine could have detrimental effects on the lives of TB patients globally.

Sutezolid is an antimycobacterial agent, developed at JHU, that has been shown to have promising activity against both drug-susceptible and drug-resistant tuberculosis (DR-TB). Early studies indicate that addition of sutezolid to the standard TB treatment regimen leads to significantly improved efficacy. Sutezolid could represent a turning point in managing this global public health crisis.

Sign the petition now to urge Johns Hopkins University to accelerate important TB innovation and ensure it's accessible for all: https://uaem.wufoo.com/forms/z1dxtbgq0ieib3a/